Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344235 | 0.81 | PDE4B (0.80) | PDE4BPDE4D | |
| SCHEMBL4332749 | 0.80 | PDE4B (0.82) | PDE4BPDE4D | |
| SCHEMBL1945446 | 0.76 | POLB (0.49) | POLBPDE4BKMT2ANR3C1TYK2 | |
| SCHEMBL1946919 | 0.76 | POLB (0.49) | POLBPDE4BKMT2ANR3C1TYK2 | |
| SCHEMBL582788 | 0.75 | POLB (0.76) | POLBPDE4BKMT2ANR3C1 | |
| SCHEMBL583870 | 0.75 | NR3C1 (0.60) | POLBPDE4BNR3C1PDE4APDE4C | |
| Bicarbonate SCHEMBL583221 | 0.74 | POLB (0.47) | POLBPDE4BKMT2ANR3C1BRD4 | |
| SCHEMBL5962961 | 0.74 | PDE4B (0.61) | POLBPDE4BNR3C1 | |
| SCHEMBL1471838 | 0.73 | POLB (0.61) | POLBPDE4BKMT2A | |
| SCHEMBL8342287 | 0.73 | PDE4B (0.77) | PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE5A, PDE3B, PDE4A | POLB 2166/4885PDE4B 4/4885KMT2A 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.